The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions
Open accessAbstract
A single subanesthetic dose of ketamine, an NMDA receptor (NMDAR) antagonist, produces rapid and sustained antidepressant actions in depressed patients, addressing a major unmet need for the treatment of mood disorders. Ketamine produces a rapid increase in extracellular glutamate and synaptic formation in the prefrontal cortex, but the initial cellular trigger that initiates this increase and ketamine's behavioral actions has not been identified. To address this question, we used a combination of viral shRNA and conditional mutation to produce cell-specific knockdown or deletion of a key NMDAR subunit, GluN2B, implicated in the actions of ketamine. The results demonstrated that the antidepressant actions of ketamine were blocked by GluN2B-NMDAR knockdown on GABA (Gad1) interneurons, as well as subtypes expressing somatostatin (Sst) or parvalbumin (Pvalb), but not glutamate principle neurons in the medial prefrontal cortex (mPFC). Further analysis of GABA subtypes showed that cell-specific knockdown or deletion of GluN2B in Sst interneurons blocked or occluded the antidepressant actions of ketamine and revealed sex-specific differences that are associated with excitatory postsynaptic currents on mPFC principle neurons. These findings demonstrate that GluN2B-NMDARs on GABA interneurons are the initial cellular trigger for the rapid antidepressant actions of ketamine and show sex-specific adaptive mechanisms to GluN2B modulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This behavioral effect corresponded to a disinhibition of layer 5 mPFC pyramidal neurons whereby inhibition of GABA signaling strengthened pyramidal neuron activity.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Gerhard et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The genetic manipulation alone appeared to reduce immobility relative to controls to a point where ketamine could not elicit a further reduction.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Gerhard et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“using a genetic knockdown approach in mice found that loss of GluN2B in medial PFC (mPFC GABAergic interneurons, and specifically in those expressing somatostatin (SST) and parvalbumin (PV), occluded the antidepressant-like effects of ketamine in the forced swim test (Gerhard et al., 2020).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Gerhard et al., 2020
In the citing paper
“Furthermore, knock-down and deletion of critical ketaminesensitive NMDARs from either somatostatin-or parvalbuminexpressing interneurons alters baseline behaviors in the FST and other tasks and eliminates the ability of ketamine to change these behaviors in unstressed mice [210].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [210]
In the citing paper
“Furthermore, knock-down and deletion of critical ketaminesensitive NMDARs from either somatostatin-or parvalbuminexpressing interneurons alters baseline behaviors in the FST and other tasks and eliminates the ability of ketamine to change these behaviors in unstressed mice [210].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [210]
In the citing paper
“As in the hippocampus, ketamine inhibits the discharge of interneurons in the PFC and reduces spontaneous IPSCs in pyramidal cells acutely [210], while restoring inhibition at later timepoints corresponding to its behavioral actions [211].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [210]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mouse brain in stereotaxic coordinates
Konsman, J. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(03)00088-x · Cited by 16,796
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Interneurons of the neocortical inhibitory system
Markram, H., Toledo-Rodriguez, M., Wang, Y., Gupta, A., Silberberg, G., & Wu, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1519 · Cited by 2,954
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationRational siRNA design for RNA interference
Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S., & Khvorova, A. (2004) · Nature Biotechnology · doi:10.1038/nbt936 · Cited by 2,094
GABAergic Interneurons in the Neocortex: From Cellular Properties to Circuits
Tremblay, R., Lee, S., & Rudy, B. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.033 · Cited by 2,033
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Self-citation
Research works printed but not linked: 1
- 10.1016/j.nbd.2019 · DOI
Cited by
Sorted by citations
Items 101–200 of 345
Ben‐Azu, B., Fokoua, A. R., Annafi, O. S., Adebayo, O. G., del Re, E. C., Okuchukwu, N., Aregbesola, G. J., Ejenavi, A.-E. C., Isiwele, D. M., Efezino, A. J., et al. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.09.003 · Cited by 25
Szpręgiel, I., & Bysiek, A. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00660-y · Cited by 28
Lourenço, J., Koukouli, F., & Bacci, A. (2020) · Cortex · doi:10.1016/j.cortex.2020.08.015 · Cited by 25
Ye, T., Bartlett, M. J., Sherman, S. J., Falk, T., & Cowen, S. L. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113670 · Cited by 30
VanderZwaag, J., Halvorson, T., Dolhan, K., Šimončičová, E., Ben‐Azu, B., & Tremblay, M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03772-0 · Cited by 28
Impact of stress on inhibitory neuronal circuits, our tribute to Bruce McEwen
Pérez-Rando, M., Carceller, H., Castillo-Gómez, E., Bueno-Fernández, C., García-Mompó, C., Gilabert‐Juan, J., Guirado, R., Pesarico, A. P., & Nácher, J. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100460 · Cited by 24
KATO, T. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109325 · Cited by 26
Xue, S.-G., He, J., Lu, L.-L., Song, S.-J., Chen, M., Wang, F., & Chen, J. (2023) · Nature Communications · doi:10.1038/s41467-023-42780-8 · Cited by 24
Grieco, S. F., Qiao, X., Johnston, K. G., Chen, L., Nelson, R. R., Lai, C., Holmes, T. C., & Xu, X. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01255-4 · Cited by 24
Ren, L. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110910 · Cited by 23
Kutlu, M. D., Köse, S., & Akıllıoğlu, K. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114386 · Cited by 24
Novel approaches to clinical trial design in cancer neuroscience
Jones, G., Anderson, J. L., Nguyen, P. T., Gleber‐Netto, F. O., Hwang, W. L., Puduvalli, V. K., Monje, M., & Amit, M. (2025) · Neuron · doi:10.1016/j.neuron.2025.08.015 · Cited by 24
The Ketamine Antidepressant Story: New Insights
Alshammari, T. K. (2020) · Molecules · doi:10.3390/molecules25235777 · Cited by 22
Ketamine's schizophrenia-like effects are prevented by targeting PTP1B
Qin, Z., Zhang, L., ZASLOFF, M. A., Stewart, A. F. R., & Chen, H. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105397 · Cited by 25
The Sexual Dimorphic Synapse: From Spine Density to Molecular Composition
Uhl, M., Schmeißer, M. J., & Schumann, S. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.818390 · Cited by 22
Lin, J., Ling, F., Huang, P., Chen, M., Song, M., Lu, K., & Wang, W. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.874137 · Cited by 23
Burgdorf, J. S., Zhang, X., Stanton, P. K., Moskal, J. R., & Donello, J. E. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac043 · Cited by 23
Aoki, C. J., & Santiago, A. N. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.990354 · Cited by 20
Increased use of ketamine for the treatment of depression: Benefits and concerns
Na, K., & Kim, Y. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110060 · Cited by 23
Shi, X., Zhang, Q., Li, J., Liu, X., Zhang, Y., Huang, M., Fang, W., Xu, J., Yuan, T., Xiao, L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109612 · Cited by 21
Lee, B., Pothula, S., Wu, M., Kang, H., Girgenti, M. J., Picciotto, M. R., Dileone, R., Taylor, J. R., & Duman, R. S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01498-7 · Cited by 22
Self-citationNewton, D. F., Oh, H., Shukla, R., Misquitta, K., Fee, C., Banasr, M., & Sibille, E. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.10.015 · Cited by 19
Liu, L., Zou, Z., Yang, J., Li, X., Zhu, B., Zhang, H., Sun, Y., Zhang, Y., Zhang, Z., & Wang, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.645638 · Cited by 21
Self-citationLiu, S.-Z., Yang, J., Chen, L., Wang, P., & Li, L. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175385 · Cited by 21
Cholewinski, T., Pereira, D., Moerland, M., & Jacobs, G. E. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211036814 · Cited by 20
Lewis, V., Rodrigue, B., Arsenault, E., Zhang, M., Taghavi‐Abkuh, F., Silva, W. C. C., Myers, M., Matta‐Camacho, E., & Aguilar‐Valles, A. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15652 · Cited by 21
Targeting prefrontal cortex GABAergic microcircuits for the treatment of alcohol use disorder
Fish, K. N., & Joffe, M. E. (2022) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2022.936911 · Cited by 20
Cai, M., Zhu, Y., Shanley, M. R., Morel, C., Ku, S. M., Zhang, H., Shen, Y., Friedman, A. K., & Han, M.-H. (2023) · Neurobiology of Stress · doi:10.1016/j.ynstr.2023.100565 · Cited by 18
Wu, H., Wu, W., Fan, H., Liu, L.-E., Zhan, J., Li, Y.-H., Chen, C., Jiang, S., Xiong, J., Yu, Z.-M., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01323-3 · Cited by 22
New investigational agents for the treatment of major depressive disorder
Pochwat, B., Krupa, A. J., Siwek, M., & Szewczyk, B. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2113376 · Cited by 22
Peng, F., Fan, J., Ge, T., Liu, Q. Q., & Li, B. J. (2020) · Cell Proliferation · doi:10.1111/cpr.12804 · Cited by 19
Saez, E., Erkoreka, L., Moreno-Calle, T., Berjano, B., González-Pinto, A. M., Basterreche, N., & Arrúe, A. (2022) · World Journal of Psychiatry · doi:10.5498/wjp.v12.i7.884 · Cited by 20
Identification of Neurensin-2 as a novel modulator of emotional behavior
Umschweif, G., Medrihan, L., Guillén-Samander, A., Wang, W., Sagi, Y., & Greengard, P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01058-5 · Cited by 18
Deyama, S., Aoki, S., Sugie, R., Fukuda, H., Shuto, S., Minami, M., & Kaneda, K. (2023) · Neurotherapeutics · doi:10.1007/s13311-022-01337-1 · Cited by 18
Role of GABAergic system in the comorbidity of pain and depression
Yang, S., Zhang, B., Wang, D., Hu, S.-W., Wang, W., Liu, C., Wu, Z., & Yang, C. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110691 · Cited by 19
The Role of Extrasynaptic GABA Receptors in Postpartum Depression
Feng, Y. F., Zhou, Y., & Duan, K. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03574-7 · Cited by 20
Amici, M., Lee, Y., Pope, R. J. P., Bradley, C. A., Cole, A. R., & Collingridge, G. L. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14841 · Cited by 17
Resolvins as potential candidates for the treatment of major depressive disorder
Deyama, S., Minami, M., & Kaneda, K. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.05.002 · Cited by 18
Gagne, C., Piot, A., & Brake, W. G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.797577 · Cited by 18
Zhou, B., Li, J., Wu, A., Wang, X., Cheng, L., Yang, G., Gao, D., & Zhu, C. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1587986 · Cited by 18
Hales, C. A., Bartlett, J., Arban, R., Hengerer, B., & Robinson, E. S. J. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00797-3 · Cited by 20
A review of potential neuropathological changes associated with ketamine
Nogo, D., Nazal, H., Song, Y., Teopiz, K. M., Ho, R., McIntyre, R. S., Lui, L. M. W., & Rosenblat, J. D. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2071867 · Cited by 21
Ketamine and Zinc: Treatment of Anorexia Nervosa Via Dual NMDA Receptor Modulation
Mitchell, J., Hermens, D. F., Bennett, M. R., Can, A., & Lagopoulos, J. (2023) · CNS Drugs · doi:10.1007/s40263-022-00984-4 · Cited by 18
Goodwin‐Groen, S., Dong, Y., & Aoki, C. J. (2023) · International Journal of Eating Disorders · doi:10.1002/eat.24036 · Cited by 19
The role of NMDARs in the anesthetic and antidepressant effects of ketamine
Zhou, L., & Duan, J. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14464 · Cited by 17
Linguiti, S., Vogel, J. W., Sydnor, V. J., Pines, A. R., Wellman, N., Basbaum, A. I., Eickhoff, C. R., Eickhoff, S. B., Edwards, R. R., Larsen, B., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105421 · Cited by 18
Strong, C. E., & Kabbaj, M. (2020) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.593860 · Cited by 17
Opioid modulation of prefrontal cortex cells and circuits
Cole, R. H., Moussawi, K., & Joffe, M. E. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109891 · Cited by 16
The role of mGluR5 on the therapeutic effects of ketamine in Wistar rats
Gokalp, D., & Ünal, G. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06571-3 · Cited by 16
Liu, B., Du, Y., Xu, C. S., Liu, Q., & Zhang, L. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148375 · Cited by 18
Speigel, I. A., & Hemmings, H. C. (2022) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2021.812905 · Cited by 19
Chen, B., Xu, J., Chen, S., Mou, T., Wang, Y., Wang, H., Zhang, Z., Ren, F., Wang, Z., Jin, K., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.031 · Cited by 15
Antidepressant-like Effects of Representative Types of Food and Their Possible Mechanisms
Piao, J., Wang, Y., Zhang, T., Zhao, J., Lv, Q., Ruan, M., Yu, Q., & Li, B. (2023) · Molecules · doi:10.3390/molecules28196992 · Cited by 16
Zhang, Q., Xue, Y., Wei, K., Wang, H., Ma, Y., Wei, Y., Fan, Y., Gao, L., Yao, H. P., Wu, F., et al. (2023) · Advanced Science · doi:10.1002/advs.202303503 · Cited by 14
Li, J., Temizer, R., Chen, Y.-W., & Aoki, C. J. (2024) · Brain Structure and Function · doi:10.1007/s00429-023-02740-w · Cited by 13
Yi, G.-L., Zhu, M.-Z., Cui, H.-C., Yuan, X.-R., Liu, P., Tang, J., Li, Y.-Q., & Zhu, X.-H. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108947 · Cited by 14
Psychedelics, epilepsy, and seizures: a review
Freidel, N., Kreuder, L., Rabinovitch, B. S., Chen, F. Y., Huang, R. S., & Lewis, E. C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1326815 · Cited by 14
Cao, K., Zhong, J., Wang, S., Shi, Y., Bai, S., Zhao, J., Yang, L., Liang, Q., Deng, D., & Zhang, R. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118040 · Cited by 15
Bernardo, A. M., Marcotte, M. D., Wong, K. D., Sharmin, D., Pandey, K. P., Cook, J. M., Sibille, E. L., & Prévot, T. D. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.12.001 · Cited by 15
Widman, A. J., & McMahon, L. L. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.05.001 · Cited by 13
CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
Nguyen, T. M. L., McGowan, J. C., & Gardier, A. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108936 · Cited by 17
Wang, S., Tang, S., Huang, J., & Chen, H. (2022) · General Psychiatry · doi:10.1136/gpsych-2022-100922 · Cited by 15
García‐Gutiérrez, M. S., Navarro, D., Torregrosa, A. B., Viudez‐Martínez, A., Giner, S., & Manzanares, J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.07.003 · Cited by 14
Existence of multiple transitions of the critical state due to anesthetics
Curic, D., Ashby, D. M., McGirr, A., & Davidsen, J. (2024) · Nature Communications · doi:10.1038/s41467-024-51399-2 · Cited by 14
Pompili, M., Sarli, G., Erbuto, D., Manfredi, G., & Comparelli, A. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000455 · Cited by 17
Ahtiainen, A., Annala, I., Rosenholm, M., Kohtala, S., Hyttinen, J., Tanskanen, J. M. A., & Rantamäki, T. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109481 · Cited by 12
Hu, Y., Feng, Y., Luo, H., Zhu, X.-N., Chen, S., Yang, K., Deng, Z., Luo, M., Du, W., Wang, Q., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115086 · Cited by 11
Zhu, Y., Wu, T., Jiao, Q., Chai, H., Wang, Y., Tian, C., Xue, Q., Li, K., Wang, P., Li, Z., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx2666 · Cited by 13
Joffe, M. E., Santiago, C. I., Vermudez, S. A. D., Fisher, N. M., Dogra, S., Niswender, C. M., & Conn, P. J. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01041-2 · Cited by 12
Kojic, M., Saelens, J., Kadriu, B., Zarate, C. A., & Kraus, C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_313 · Cited by 12
The NMDA receptor subunit GluN2D is a potential target for rapid antidepressant action
Vestring, S., Veleanu, M., Perez, M. C., Schuberth, L. E., Bronnec, M., Li, A., Würz, L. M., Erdogdu, F., Stocker, J., Moos, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66774-w · Cited by 13
Yao, H., Wang, X., Chi, J., Chen, H., Liu, Y., Jiayi, Y., Yu, J., Ruan, Y., Xiang, X., Pi, J., et al. (2024) · Molecules · doi:10.3390/molecules29050964 · Cited by 11
Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023
Zhao, L.-Y., Zhang, G.-F., Lou, X.-J., Hashimoto, K., & Yang, J. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01809-9 · Cited by 11
Jiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 11
Zhang, J., Duan, J., Li, W., Wang, X., Ren, S., Ye, L., Liu, F., Tian, X., Xie, Y., Huang, Y., et al. (2025) · Science Advances · doi:10.1126/sciadv.adq0444 · Cited by 11
Bowman, C., Richter, U., Jones, C. R., Agerskov, C., & Herrik, K. F. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.737295 · Cited by 12
Ready for a “breakthrough” with ketamine? A look at recent pharmacological insights!
Himmelseher, S., & Kochs, E. F. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001017 · Cited by 10
Temizer, R., Chen, Y., & Aoki, C. J. (2022) · Synapse · doi:10.1002/syn.22253 · Cited by 10
Liu, L., Huang, H., Li, Y., Zhang, R., Wei, Y., & Wu, W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.707326 · Cited by 9
Flowers, J. C., Vetter, P. E., Wiles, M. J., Roh, S. H., Black, E. R., Bouckova, E., Wustrau, M. H., Lee, R., Lee, S.-H., & Kim, S. (2025) · The FASEB Journal · doi:10.1096/fj.202501763r · Cited by 11
Mechanism-guided identification of antidepressant G protein-coupled receptor drug targets
Munguba, H., Arefin, A., Hasegawa, R., Posa, L., Romano, G. R., Peddada, T., Donatelle, A., Singh, A., Gutzeit, V. A., Vijay, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.04.006 · Cited by 10
Freitas, A. E., Feng, B., Woo, T., Galli, S., Baker, C., Ban, Y., Truong, J., Beyeler, A., & Zou, Y. (2024) · Nature Communications · doi:10.1038/s41467-024-48257-6 · Cited by 9
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Pharmaceuticals · doi:10.3390/ph16040634 · Cited by 11
Li, C., Zhang, J., Liu, H., Yuan, H., Cai, J., Fogaça, M. V., & Zhang, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115137 · Cited by 8
Oberst, P., Xu, N., Munguba, H., Zhang, C., Zhong, A., Zhou, T., Liston, C. M., Levitz, J., & Studer, L. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.08.011 · Cited by 8
Fernandes, G. G., Costa, K. C. M., Scomparin, D. S., Freire, J. B., Guimarães, F. S., & Campos, A. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.782831 · Cited by 8
Prepubertal ovariectomy confers resilience to stress-induced anxiety in adult female mice
Woodward, E. M., Ringland, A., Ackerman, J., & Coutellier, L. D. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105997 · Cited by 8
Subanesthetic ketamine exerts antidepressant-like effects in adult rats exposed to juvenile stress
Aikawa, K., Yoshida, T., Ohmura, Y., Lyttle, K. A., Yoshioka, M., & Morimoto, Y. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146980 · Cited by 8
Wang, Y., Yin, X., He, X., Zhou, C.-M., Shen, J.-C., & Tong, J. (2021) · Aging · doi:10.18632/aging.202684 · Cited by 8
Izumi, Y., Mennerick, S. J., Doherty, J., & Zorumski, C. F. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000376 · Cited by 8
Arrabal-Gómez, C., Beltran-Casanueva, R., Hernández-García, A., Bayolo-Guanche, J. V., Barbancho-Fernández, M. A., Castro, P. S., & Narváez, M. (2024) · Cells · doi:10.3390/cells13080669 · Cited by 7
Arrabal-Gómez, C., Serrano-Castro, P. J., Sánchez‐Pérez, J. A., García‐Casares, N., Fuxé, K., Borroto-Escuela, D., & Narváez, M. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2342524 · Cited by 7
Substance specific EEG patterns in mice undergoing slow anesthesia induction
Obert, D. P., Killing, D., Happe, T., Tamas, P., Altunkaya, A., Dragovic, S. Z., Kreuzer, M., Schneider, G. H., & Fenzl, T. (2024) · BMC Anesthesiology · doi:10.1186/s12871-024-02552-3 · Cited by 7
Acero-Castillo, M. C., Correia, M. B. M., Caixeta, F. V., Motta, V., Barros, M., & Maior, R. S. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110088 · Cited by 7
The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine
Park, D., Lee, G., Lee, W.-G., Kim, B. S., Lee, Y., & Kim, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03100-2 · Cited by 11
Exploring Biological Risk Factors in Treatment-Resistant Depression
Lievanos-Ruiz, F. J., & Navarro, B. F. (2025) · Psychiatry International · doi:10.3390/psychiatryint6040134 · Cited by 7
New advances in small molecule drugs targeting NMDA receptors
Zeng, Y., Qu, Z.-Y., Zhu, Q., Wang, H., Zhou, Y., & Gao, Z.-B. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01675-8 · Cited by 8
Cortical Mechanisms Contributing to Ketamine-Induced Dissociation
Bera, K., Looger, L. L., Proekt, A., & Cichon, J. (2025) · The Neuroscientist · doi:10.1177/10738584251403946 · Cited by 9
O’Regan, G., Plummer, Z., Christie, B. R., Shultz, S. R., & Allen, J. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03717-2 · Cited by 11
Beanes, G., Caliman‐Fontes, A. T., Souza‐Marques, B., Silva, H. D. S., Leal, G. C.-G., Carneiro, B. A., Guerreiro‐Costa, L. N. F., Figueiredo, A. V., Figueiredo, C. A., Lacerda, A. L. T., et al. (2022) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000517 · Cited by 7
Metadata
- Authors
- Gerhard, D. M., Pothula, S., Liu, R.-J., Wu, M., Li, X.-Y., Girgenti, M. J., Taylor, S. R., Duman, C. H., Delpire, E., Picciotto, M., Wohleb, E. S., & Duman, R. S.
- Affiliations
- Yale University (US)
- Vanderbilt University (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-01-27
- Volume
- 130
- Issue
- 3
- Pages
- 1336-1349
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7269589
- OpenAlex
- W2991582092
- Cited by
- 345
- References
- 61
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 51 · 2023: 61 · 2022: 55 · 2021: 44 · 2020: 43
- FWCI
- 22.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH093897, MH105910, MH077681)
- National Institute on Drug Abuse (DA14241)
- National Institute on Alcohol Abuse and Alcoholism (AA013514)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- ketamine, rapid antidepressant effects, GABAergic interneurons, GluN2B, NMDA receptor, somatostatin interneurons, parvalbumin interneurons, medial prefrontal cortex, depression, sex differences, excitatory postsynaptic currents, glutamate release, synaptic plasticity
- MeSH terms
- Animals, Antidepressive Agents, Female, Glutamate Decarboxylase, Interneurons, Ketamine, Male, Mice, Transgenic, Parvalbumins, Sex Characteristics, Somatostatin, Receptors, N-Methyl-D-Aspartate, Mice, Gene Knockout Techniques, GABAergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
